Vertex Pharmaceuticals VRTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.03B-13.4% | $1.19B+10.0% | $1.08B+4.8% | $1.03B+59.8% | $646.3M— | ||
| $55.9M+0.4% | $55.7M+3.1% | $54M+4.4% | $51.7M+6.8% | $48.4M+4.1% | ||
| $166.4M+5.6% | $157.6M-19.1% | $194.9M+16.5% | $167.3M+0.7% | $166.1M-1.0% | ||
| -$39.8M-140% | $99.4M+65.9% | $59.9M+226% | $18.4M-89.2% | $169.6M— | ||
| $97.7M+26.2% | $77.4M-41.0% | $131.1M-11.8% | $148.6M-11.1% | $167.1M+13.3% | ||
| $35.6M-7.0% | $38.3M+208% | -$35.3M-564% | $7.6M-71.0% | $26.2M+212% | ||
| $23.1M-78.2% | $105.8M+26.1% | $83.9M+233% | -$63.2M-387% | $22M— | ||
| $1.43B+187% | $498M-59.9% | $1.24B+15.7% | $1.07B+31.0% | $818.9M+765% | ||
| $133.4M-10.7% | $149.4M+46.8% | $101.8M-30.1% | $145.7M+258% | $40.7M-56.0% | ||
| $2.51B+104% | $1.23B-8.5% | $1.35B-38.1% | $2.17B+31.9% | $1.65B-23.7% | ||
| -$431.9M-49.9% | -$288.1M-146% | -$117M+75.9% | -$484.5M-768% | -$55.8M+93.2% | ||
| $336.9M+162% | $128.4M-88.0% | $1.07B+173% | $391.8M-8.0% | $426.1M+2.0% | ||
| $228.5M+9,040% | $2.5M-97.3% | $91M+1,442% | $5.9M-97.8% | $270.5M+3,605% | ||
| -$538.8M-598% | -$77.2M+93.3% | -$1.15B-231% | -$349.2M+48.7% | -$680.4M-73.9% | ||
| -$40.3M-652% | $7.3M— | $0-100% | $57.2M+87.5% | $30.5M+164% | ||
| $417.1M+198% | $140M— | $0-100% | $296.6M+162% | $113.2M+117% | ||
| $3.2M+6.7% | $3M-6.3% | $3.2M-8.6% | $3.5M+29.6% | $2.7M0.0% | ||
| $0— | $0— | $0— | $0-100% | $379M— | ||
| $70.5M+111% | -$664.5M-300% | $332.9M+99.8% | $166.6M+246% | $48.1M— | ||
| -$173.4M-169% | $250.6M+513% | $40.9M-46.5% | $76.4M+172% | $28.1M-82.9% | ||
| $5M+122% | -$23.1M— | $0+100% | -$57.8M-47.4% | -$39.2M-139% | ||
| $0-100% | $15.9M— | $0-100% | $4.3M-18.9% | $5.3M-82.8% | ||
| $2.21B+102% | $1.09B-17.9% | $1.33B-27.7% | $1.84B+12.3% | $1.64B+12.1% | ||
| $27M-50.0% | $54M+584% | $7.9M-83.9% | $49.1M+194% | $16.7M-51.3% | ||
| -$400K-136% | $1.1M0.0% | $1.1M-45.0% | $2M+500% | -$500K-156% | ||
| $82.3M-78.9% | $389.4M-18.8% | $479.6M-6.6% | $513.3M+178% | $184.4M-32.2% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $1.29B+271% | $348.6M-69.4% | $1.14B+22.9% | $927.4M+19.2% | $778.2M+494% | ||
| $1.29B+271% | $348.6M-69.4% | $1.14B+22.9% | $927.4M+19.2% | $778.2M+494% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Vertex Pharmaceuticals generate?
- Vertex Pharmaceuticals (VRTX) generated $4.2B in operating cash flow over the trailing twelve months.
- What is Vertex Pharmaceuticals's free cash flow?
- After $530.3M of capital expenditures, Vertex Pharmaceuticals's free cash flow was $3.7B over the trailing twelve months, up 207.9% year over year.
- Where does Vertex Pharmaceuticals's cash flow data come from?
- Every line is extracted from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
